The multidisciplinary colposcopy meeting: recommendations for future service provision and an analysis of clinical decision making

Size: px
Start display at page:

Download "The multidisciplinary colposcopy meeting: recommendations for future service provision and an analysis of clinical decision making"

Transcription

1 DOI: /j x Gynaecological oncology The multidisciplinary colposcopy meeting: recommendations for future service provision and an analysis of clinical decision making JE Palmer, a K Wales, b K Ellis, c N Dudding, c,d J Smith, d,e JA Tidy a a Department of Gynaecological Oncology/Jessop Wing Colposcopy Unit, Sheffield Hospitals NHS Trust, Sheffield, UK b Department of Obstetrics & Gynaecology, Sheffield Hospitals NHS Trust, Sheffield, UK c Department of Cytology, Sheffield Hospitals NHS Trust, Sheffield, UK d East Pennine Cytology Training Centre, Tingley, Leeds, UK e Department of Histpoathology, Sheffield Hospitals NHS Trust, Sheffield, UK Correspondence: Dr J Palmer, c/o Department of Gynaecological Oncology, Royal Hallamshire Hospital, Glossop Rd, Sheffield, S10 2JF, UK. palmer006@btinternet.com Accepted 26 May Objective In 2004 the NHS Cervical Screening Programme (NHSCSP) recommended that multidisciplinary meetings should be incorporated into patient management. No data has been provided since then regarding its functionality or benefits. We aim to address this issue. Design Retrospective review. Setting Jessop Wing colposcopy multidisciplinary meeting (MDM), Sheffield, UK. Population All women referred to the MDM from September 2003 to September Methods Retrospective review of the colposcopy database (Sept 2003 Sept 2009), cross-referenced with multidisciplinary team (MDT) letters, patient notes and the hospital results reporting system. Baseline statistics were used for data analysis. Main outcome measures Indications for MDT referral; concordance rates from cytopathology and histopathology review; concordance rates between MDT treatment decisions and final patient management. Results A total of 535 cases were discussed at 62 MDT meetings during the allocated study period. referral cytology and cervix punch biopsy was the most common referral (49%). Cytology and histology review concurred with the initial reports in 75.8 and 97.8% of cases, respectively; the MDT decision was concordant with the final patient management in 97% of cases. The main reason for discordance (67%) resulted from patient factors. Conclusions When significant discrepancies exist between colposcopy, cytology and histopathology, then MDT discussion seems pertinent as MDT discussion can lead to the avoidance of over-treatment. To improve timeliness of treatment, MDT meetings should occur at least monthly. The results of each case discussion should be recorded in the patient case notes, the minutes of each meeting should be circulated to all MDT members and a letter describing MDT recommendations must be sent to the colposcopist responsible for patient care. Keywords Colposcopy, cytology, gynaecology, multidisciplinary team, multiprofessional. Please cite this paper as: Palmer J, Wales K, Ellis K, Dudding N, Smith J, Tidy J. The multidisciplinary colposcopy meeting: recommendations for future service provision and an analysis of clinical decision making. BJOG 2010;117: Introduction Since the introduction of the Calman Hine report in 1995, 1 the importance of multidisciplinary team (MDT) working in cancer services has been repeatedly emphasised, resulting in an MDT approach to patient cancer management being widely adopted in the UK. In 2004 the colposcopy and programme management guidelines for the NHS cervical screening programme (NHSCSP) 2 recommended that multidisciplinary meetings (MDMs) should be incorporated into patient management, including histopathology, cytopathology and colposcopy review. It was suggested that MDMs should be held at least twice a year to discuss difficult cases, cases with significant mismatch between cytopathology and colposcopy, and borderline glandular and glandular smears. The new NHSCSP document 20 (Leusley D, Leeson S. NHS Cancer Screening Programmes unpubl data) will recommend that the MDT should meet often enough to allow for the timely care of women: once each month (best practice) or no less than once every 2 months. Whereas the Improving Outcomes Guidance 3 and the Manual for Cancer Services 4 provide direction with regard 1060 ª 2010 The Authors Journal compilation ª RCOG 2010 BJOG An International Journal of Obstetrics and Gynaecology

2 The multidisciplinary colposcopy meeting to the MDT function in gynaecological cancers, further guidance regarding the colposcopy MDT is yet to be provided. Research on the effectiveness of MDMs and MDTs in cancer management is lacking, 5 8 and, although suggestions have been made regarding the advantages and disadvantages of an MDT approach to cancer care (see Table 1), no systematic reviews have yet been performed. 9 Information regarding the function and benefits of the colposcopy MDT is even rarer, with, to date, only one publication reporting an activity review. 10 Assessing the effectiveness of an MDT is fraught with difficulty as the ultimate indicator in cancer care is improved patient outcome or survival. The ability to substantiate improvements in patient care purely consequential to MDT discussion, over the general improvements in patient management resulting from advances in surgery, and radiotherapy or chemotherapy techniques, is extremely difficult to ascertain, and, despite cancer MDTs being readily accepted and established within patient management protocols, very little information is available regarding improved outcomes arising from discussion at an MDM alone. In turn, assessing the benefits of a colposcopy MDT is also extremely difficult, and is even harder to establish as there are no set indicators of improved patient outcome. Blazeby et al. 11 proposed that one method of evaluating treatment decisions is to investigate whether or not those decisions are actually implemented. As data regarding colposcopy MDMs on the whole is lacking, we shall review the indications for colposcopy referral, the concordance rates from cytopathology and histopathology review and, in reference to the proposed methods of Blazeby et al., we shall consider the concordance between MDT treatment decisions and their final implementation in patient management within our own unit. Methods The colposcopy MDM at Sheffield Hospitals NHS Trust commenced in September The MDT group consists of colposcopists, cytopathologists and histopathologists, and has previously been and is currently led by a consultant in gynaecological oncology (JT and JP, respectively). For the purposes of this paper cytopathologists are taken to include either consultant medical staff and/or consultant biomedical scientists. The meeting is currently held on a monthly basis, with all attendees included in the discussions and all members of the MDT able to make referrals to the MDM via referral proforma sheets. Decisions made at the MDM are recorded by the colposcopy lead, and letters are written to the patients named colposcopist with details of the MDT discussion. Minutes of the meeting are also circulated to all MDT members, and over the last 12 months an MDM database has been established with data prospectively added from February 2009, and data from prior discussions added retrospectively following a review of minutes, letters and patient notes. The colposcopy database was retrospectively reviewed and cross-referenced with the corresponding MDM letters and, where appropriate, patient notes. All results were cross-checked against the hospitals clinical reporting results system. To assess concordance between MDT treatment decisions and their final implementation, patient letters, notes and results were again fully examined. Baseline statistics were used for the data analysis. Results Between September 2003 and September 2009 there were 62 colposcopy MDT meetings held at Sheffield Teaching Hospitals. From September 2003 to December 2004 meetings were held every 2 months, then monthly from thereon. All meetings were quorate (i.e. were attended by at least one histopathologist, a cytopathologist and a colposcopist). Five of eight colposcopists, all cytologists and all pathologists achieved a >50% attendance rate. During the study period 535 cases were discussed in total. An average of nine women were discussed at each meeting (range 3 16) with 1 hour allocated for each meeting. The mean age of the women discussed was 39 years (range years). Forty-six women (9%) were younger than 25 years of age, and seven women (1%) were older than 65 years of age. Women were referred to the colposcopy MDM by British Society for Colposcopy and Cervical Pathology (BSCCP) certified colposcopists (90%), trainee colposcopists (7%), histopathologists (1%) and cytologists (2%). Of the certified colposcopists, consultants made 44%, colposcopy practitioners made 25% and nurse colposcopists made 31% of the referrals, which was in keeping with the unit s clinical distribution of workload. Twentyseven women (5%) were discussed at more than one meeting, with a maximum of four discussions for one woman. The most common reason for MDM referral was because of a discrepancy between referral cytology and cervix punch biopsy (49%). In total, 433 cytology specimens and 372 histology specimens were reviewed during the allocated study period. Indications for MDM referral and concordance rates between referral cytology and histopathology review are illustrated in Table 2. Where an MDT review had been requested for purposes of further management discussion, the majority were cancer cases. Although this is a relatively small number of cancer cases, this purely reflects our policy of preferably discussing these cases at the gynaecological oncology MDM. Further management was discussed in 12 cases (13%) because of the presence of a glandular abnormality, nine (10%) for persistent low-grade dyskaryosis, eight (9%) ª 2010 The Authors Journal compilation ª RCOG 2010 BJOG An International Journal of Obstetrics and Gynaecology 1061

3 Palmer et al. Table 1. Proposed advantages and disadvantages of multidisciplinary teams and multidisciplinary meetings Advantages Disadvantages Patient centred Pooling of knowledge and expertise leading to higher quality diagnosis, 7 and evidence-based decision-making. 12 Inadequate communication between MDT members could lead to confusion for patients about diagnoses, prognoses and future management plans. 9 Optimum treatment planning. 6,7 Team discussion may not necessarily improve the quality of decision making overall. 12 Optimum delivery of care. 7 Decisions made at multidisciplinary meetings are not always implemented. 11,12 May be safer because a team creates an additional defence against error by monitoring and double-checking decisions. 8 Reduction in patient anxiety because the patient has the knowledge that treatment is based upon the opinion of several experts. 8 Provides continuity of care. 8 Shown to have a positive effect on patient outcome. 6 Pathology review has been identified as resulting in appropriate patient management. 14,15 In breast cancer there is evidence that improved survival was associated with management by an MDT, 16 and that patients cared for by an MDT rather than by a series of individuals have an improved survival 10 years post diagnosis. 17 Team centred Improved communication between different specialists. 8,18 Barriers to attendance leading to limited attendance: e.g. oncologists and pathologist having several site-specific meetings to attend. 24 Constraints of job plans. Beneficial to the mental health of members. 19 Types of cases selected and attendance by key staff vary. 25 Mutually supportive environment in complex cases. 7 Time constraints within the meetings. 8 Educational opportunities: learning about new developments and clinical trials. 13,18,20,21 Multidisciplinary decisions are sometimes not even documented. 26 Platform for recruitment into clinical trials. 21,22 Ever increasing numbers of referrals and need for quick response. In oncology cases, the presence of MDT clinicians provide pathologists with additional clinical Lack of administrative support. information that may alter or affect patient diagnosis. 13,23 Institution centred Enhance communication between primary-care health professionals and hospital-based specialists. 7 Institutional resistance. 7 Quality assurance role. Time consuming for clinicians leading to manpower & logistical difficulties. 28 May enhance implementation of protocols. 8 Resource expensive. Suggested increased recruitment into trials. 21 Constraints on job planning. Pathology review: identified as cost effective. 27 In gynaecological cancer, tumour boards have led to the identification of several major diagnostic discrepancies ª 2010 The Authors Journal compilation ª RCOG 2010 BJOG An International Journal of Obstetrics and Gynaecology

4 The multidisciplinary colposcopy meeting Table 2. Concordance between referral cytology and histopathology, and MDT review Histology review regarded as under-call Histology review regarded as over-call Histology review concordant Cytology review regarded as under-call Cytology review regarded as over-call Cytology review concordant Categories for MDT Referral n (%) 9 (39%) 0 5 of 5 (100%) (4%) 14 of 23 (61%) (one sample unavailable for review) cytology and colposcopy 261 (49%) 175 of 246 (71%) 71 (29%) of 224 (98%) 1 (0.4% 4 (1.6%) cytology and punch biopsy 25 (5%) 22 of 25 (88%) 3 (12%) 0 24 of 24 (100%) 0 0 cytology and loop/knife cone 17 (3%) 2 of 2 (100%) of 17 (94%) 1 (6%) 0 biopsy and loop/knife cone Review of cytology 95 (18%) 77 of 95 (81%) 17 (18%) 1 (1%) 18 of 18 (100%) 0 0 Review of biopsy/loop/cone 16 (3%) 2 of 2 (100%) of 16 (94%) 0 1 (6%) Discussion on further 93 (17%) 33 of 37 (89%) 4 (11%) 0 64 of 65 (98%) 1 (2%) 0 management Educational discussion 4 (1%) 3 of 3 (100%) of 3 (100%) 0 0 Totals (n) (%) 535 (100%) 328 of 433 (75.8%) 104 of 433 (24%) 1 of 433 (0.2%) 364 of 372 (97.8%) 3 of 372 (0.8%) 5 of 372 (1.4%) were immunocompromised with persistent cytological abnormality, five (5%) had persistent high-grade abnormality despite prior treatment, five (5%) had an inadequate colposcopic assessment, four (4%) had vaginal or vault lesions and nine (10%) were discussed for other reasons. The four cases discussed for educational purposes only were all referred by the lead pathologist (JS). The MDT cytology review concurred with the initial cytology report in 328 cases (75.8%). Where cytological overcall was identified, this was by at least two cytological grades (i.e. high-grade dyskaryosis downgraded to lowgrade dyskaryosis). The MDT histology review concurred with the initial histology report in 364 cases (97.8%). With regard to histology under-call, one punch biopsy had been reported as normal when high-grade cervical intraepithelial neoplasia should have been reported, but a secretarial typing error was identified at the MDM. Follow-up data was available for 509 of the 535 patients (95%), as 26 women awaiting colposcopy and/or repeat cytology at 6 or 12 months post-mdt discussion had not been seen by the end of the study period. The MDT decision was concordant with final patient management in 494 of 509 women (97%). Fifteen (3%) MDT decisions failed to comply with final patient management. Reasons for non-compliance with the MDT decision are provided in Table 3. In 67% of cases in which non-compliance was reported the reason for non-compliance with MDT decisions was because of a patient factor, and in 23% the reason was because of a clinician factor. Discussion Current NHSCSP guidelines suggest that multidisciplinary meetings (MDM) should be held at least twice a year. 2 We agree with Moss et al. 10 that this is not appropriate for the volume of workload undertaken in most colposcopy units. We recommend that best practice would be to meet on a monthly basis, and, where this is not feasible, meetings should occur at least every 2 months. When a gynaecological malignancy is detected through cervical screening or colposcopy services then we recommend that these cases are reviewed by the gynaecological cancer centre MDT, as such meetings tend to occur on a weekly basis, permitting the timely care of women in keeping with the 62-day pathway guidelines for cancers detected through the cervical screening pathway. 29 Alternatively, the colposcopy MDT could be held as a distinct part of the gynaecological cancer MDT. The NHSCSP colposcopy and programme management guidelines document upgrade (unpubl data) recommends that all colposcopists attend at least 50% of MDT meetings to ensure the timely management of difficult cases and discordant results. Three colposcopists (all gynaecological ª 2010 The Authors Journal compilation ª RCOG 2010 BJOG An International Journal of Obstetrics and Gynaecology 1063

5 Palmer et al. Table 3. Reasons for non-compliance with MDT decision in final patient management MDT decision Final management outcome Patient factor Clinician factor Recommend total abdominal hysterectomy: prior large loop excision of the transformation zone, now indicating severe dyskaryosis/invasion. Repeat colposcopy and smear in 6 months. Repeat smear in 12 months. Loop excision recommended. Recommend knife cone. Cervix excised only because of patient habitus. Three women did not attend. Patient deferred to private sector. Repeat punch biopsy only at patient request. Patient declined treatment and requested conservative management. Patient did not attend. Hysterectomy performed for medical reasons. Loop excision at patient request for persistent low-grade dyskaryosis. Repeat colposcopy and smear in 6 months (clinician not at MDM) three women. Colposcopy and biopsy in 3 months discretion of colposcopist as reported atrophic changes. Other Repeat colposcopy and smear in 12 months. Punch biopsy reported at the MDM after colposcopy showed invasion: referred to the gynaecological oncology MDT oncologists) were unable to attend 50% of meetings because of other commitments. This new recommendation means that job plans may need to be re-negotiated. As numerous barriers to MDT attendance may occur (see Table 1), we support the recommendation that the results of each case discussion are not only recorded in the patient case notes with the minutes of each meeting circulated to all MDT members, but that a letter describing MDT recommendations are sent to the colposcopist responsible for patient care. This is important as individual team members find it difficult to attend every MDM, and the decisions made by the MDT on behalf of their patients need to be clear during these periods of non-attendance. 12 We also recommend the use of a colposcopy database as a further quality assurance and service review measure. Designating referral criteria for a colposcopy MDM can be difficult. Although discussion regarding discrepancy between cytology and histology seems pertinent, 10 the inclusion of all mismatch is likely to result in an extremely large MDT workload. We therefore recommend that a mismatch of at least two grades between cytology, colposcopy and histology is included at the discretion of the colposcopist. We also recommend MDT discussion for patients younger than 25 or older than 65 years in age, in whom high-grade cervical intraepithelial neoplasia is detected, or where cytological abnormality persists. Glandular abnormalities should also be reviewed at the colposcopy MDT at the clinician s discretion as, although review of all cases might be ideal, this may also lead to a significantly increased workload. 10 The referral criteria that are most difficult to define is in patients where the clinician has requested further discussion regarding future management, as these cases are often less than straightforward. We therefore agree with Moss et al. 10 that additions to the colposcopy MDM falling outside of any standardised referral criteria should be allowed at the discretion of the team. In this study it is disappointing that only four cases (<1%) were specifically included on the MDM for educational discussion. Although every case discussed could be regarded as potentially educational, and discussion regarding new developments and clinical trials occur in our MDM, these latter discussions are not recorded in our minutes. Although educational opportunities are considered to be a benefit of MDT working (see Table 1), it remains difficult to assess the educational value of the MDM, especially on an individualised basis. Little has been discussed in the literature regarding the benefits of cytology review. Moss et al. 10 found a 79% concordance rate in cytology and a 92% concordance rate in histopathology when considering MDT referrals for a discrepancy between referral cytology and loop excision histology, and these results are similar to our own findings (75.8% concordance for cytology and 97.8% for histology). As 24% of our cytology reviewed at MDT was regarded as over-call, then MDT case review may have enabled the avoidance of over-treatment in some cases. The NHSCSP is a world leader in cervical screening, developing systems and guidelines to ensure a high quality of cervical screening throughout the UK. Sheffield also benefits from having a high diagnostic accuracy cytology laboratory exhibiting high specificity. In the international setting it is possible that there might be more cases of discordant cytology in laboratories with poorer sensitivities/ 1064 ª 2010 The Authors Journal compilation ª RCOG 2010 BJOG An International Journal of Obstetrics and Gynaecology

6 The multidisciplinary colposcopy meeting specificities, and in these circumstances MDT discussion might result in improved patient care. Anecdotally, there has been a degree of skepticism as to whether MDTs are of value, 29 yet assessing the value of an MDT is fraught with difficulty. In this case we have used Blazeby s 11 model, by investigating whether MDT treatment decisions were actually implemented. The MDT decision was concordant with final patient management in 97% of cases. The responsible clinician was not present at the MDM in all four cases of discordance with the MDT decision arising from a clinician factor. In future, we recommend that all such cases are re-discussed at the MDM. As in this study, MDT decision discordance is suggested to arise almost always from patients receiving a more conservative treatment than originally planned. 11 Patients may decline treatment, or patients and clinicians may opt for a more conservative approach to management. Whenever possible, however, patient wishes should be accounted for at the time of decision making. Conclusion Multidisciplinary team working has been widely incorporated into UK practice in cancer care, and more recently into non-cancer patient management, with the colposcopy MDT being one such example. There is little evidence, however, for any direct effect of MDT working on improved patient outcomes under any circumstances. Where significant discrepancies exist between colposcopy, cytology and histopathology, discussion at an MDM seems pertinent, as colposcopy, cytology and histopathology are well known to have associated false-negative and false-positive rates. An MDT discussion can result in the avoidance of over-treatment, and the safe and effective treatment of high-grade precancerous lesions. 30,31 In an aim to evaluate the treatment decisions made in our own colposcopy MDT, we investigated whether or not decisions were actually implemented. We found high concordance rates (97%). The majority of discordance came from patient factors, largely where patients wished for an alternative management approach to that planned by the MDT. If anything, this has highlighted that patient wishes need to be accounted for prior to discussion at the MDM, whenever appropriate. Disclosure of interests The authors state that they have no conflicts of interest: there were no affiliated sponsors and no funding for this article. Contribution to authorship JP conceived, designed and performed the study, analysed the data and wrote the paper. KW analysed the data and wrote the paper. ND, JS and JT conceived and designed the study, and wrote the paper. Details of ethics approval Ethical approval was not required for this study. Funding There was no associated funding. Acknowledgements We would like to thank Sue Roberts (Colposcopy MDT Co-coordinator) and Lesley Mercer (Colposcopy Secretary) for their data retrieval and database management. j References 1 Calman K, Hine D. Expert Advisory Group on Cancer. A policy framework for commissioning cancer services. London: Department of Health, Department of Health. Colposcopy and programme management: Guidelines for the NHS cervical screening Programme. NHSCSP Publication No :17, 20. Available at: cervical/publications/nhscsp20.html. Accessed 12 December The Department of Health. Improving outcomes in gynaecological cancers. NHS Executive. 1999:12. Available at Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/ DH_40. Accessed 12 December, NHS National Cancer Action Team. Manual for Cancer Services 2008: Gynaecology Measures. London: 7th Nov 2008, Department of Health. Available at: Publications/PublicationsPolicyAndGuidance/DH_ Accessed 12 December Carter S, Garside P, Black A. Multidisciplinary team working, clinical networks, and chambers; opportunities to work differently in the NHS. Qual Saf Health Care 2003;12(Suppl 1):i Houssami N, Sainsbury R. Breast cancer: multidisciplinary care and clinical outcomes. Eur J Cancer 2006;42: Fleissig A, Jenkins V, Catt S, Fallowfield L. Multidisciplinary teams in cancer care: are they effective in the UK? Lancet Oncol 2006;7: Kidger J, Murdoch J, Donovan JL, et al. Clinical decision-making in a multidisciplinary gynaecological cancer team: a qualitative study. BJOG 2009;116: Jenkins VA, Fallowfield LJ, Poole K. Are members of multidisciplinary teams in breast cancer aware of each other s informational roles? Qual Health Care 2001;10: Moss EL, Byrom J, Owen G, et al. Multidisciplinary colposcopy clinicopathology correlation meetings: an activity review. J Low Genit Tract Dis 2009;13: Blazeby JM, Wilson L, Metcalfe C, et al. Analysis of clinical decision making in multidisciplinary cancer teams. Ann Oncol 2006;17: Kee F, Owen T, Leathem R. Decision making in a multidisciplinary cancer team: does team discussion result in better quality decisions? Med Deci Making 2004;24: Santoso JT, Schwertner B, Coleman RL, et al. Tumor board in gynecologic oncology. Int J Gynecol Cancer 2004;14: Wurzer JC, Al-Saleem TI, Hanlon AL, et al. Histopathologic review of prostate biopsies from patients referred to a comprehensive cancer center: correlation of pathologic findings, analysis of cost, and impact on treatment. Cancer 1998;83: ª 2010 The Authors Journal compilation ª RCOG 2010 BJOG An International Journal of Obstetrics and Gynaecology 1065

7 Palmer et al. 15 Lee AH, Mead GM, Theaker JM. The value of central histopathological review of testicular tumours before treatment. BJU Int 1999; 84: Sainsbury R, Haward B, Rider L, et al. Influence of clinician workload and patterns of treatment on survival from breast cancer. Lancet 1995;345: Gillis CR, Hole DJ. Survival outcome of care by specialist surgeons in breast cancer: a study of 3786 patients in the West of Scotland. Br Med J 1996;312: Ruhstaller T, Roe H, Thürlimann B, et al. The multidisciplinary meeting: an indispensable aid to communication between different specialities. Eur J Cancer 2006;42: Haward R, Amir Z, Borril C, et al. Breast cancer teams; the impact of constitution, workload, and methods of operation on their effectiveness. Br J Cancer 2003;89: Twelves CJ, Thomson CS, Young J, et al. Entry into clinical trials in breast cancer: the importance of specialist teams. Scottish Breast Cancer Focus Group and Scottish Cancer Therapy Network. Eur J Cancer 1998;34: Magee LR, Laroche CM, Gilligan D. Clinical trials in lung cancer: evidence that a programmed investigation unit and a multidisciplinary clinic may improve recruitment. Clin Oncol (R Coll Radiol) 2001;13: Whelan JM, Griffith CDM, Archer T. Breast cancer multi-disciplinary teams in England: much achieved but still more to be done. The Breast 2006;15: Chan Y-M, Cheung AN-Y, Cheng DK-L, et al. Pathology slide review in gynecologic oncology: routine or selective? Gynecol Oncol 1999;75: Bradley PJ, Zutsci B, Nutting CM. An audit of clinical resources available for the care of head and neck cancer patients in England. Clin Oncol 2005;17: Griffith C, Turner J. United Kingdom National Health Service, Cancer Services Collaborative Improvement Partnership. Redesign of cancer services: a national approach. Eur J Surg Oncol 2004;30 (Suppl. 1): Macaskill EJ, Thrush S, Walker EM, Dixon JM. Surgeons views on multi-disciplinary breast meetings. Eur J Cancer 2006;42: Epstein JI, Walsh PC, Sanfilippo F. Clinical and cost impact of second-opinion pathology. Review of prostate biopsies prior to radical prostatectomy. Am J Surg Pathol 1996;20: Haward RA. Using service guidance to shape the delivery of cancer services: experience in the UK. Br J Cancer 2003;89(Suppl. 1): S Department of Health. Going Further on Cancer Waits. London: Department of Health, UK 2 December Kelly MJ, Lloyd TDR, Marshall D, et al. A snapshot of MDT working and patient mapping in the UK colorectal cancer centres in Colorectal Dis 2003;5: Dina R. Recommendations that could improve performance of colposcopy and cytology. Cytopathology 2008;19: ª 2010 The Authors Journal compilation ª RCOG 2010 BJOG An International Journal of Obstetrics and Gynaecology

POLICY FOR CLINICAL AUDIT OF NEW CASES OF INVASIVE CERVICAL CANCER AND DISCLOSURE OF RESULTS

POLICY FOR CLINICAL AUDIT OF NEW CASES OF INVASIVE CERVICAL CANCER AND DISCLOSURE OF RESULTS POLICY FOR CLINICAL AUDIT OF NEW CASES OF INVASIVE CERVICAL CANCER AND DISCLOSURE OF RESULTS Reference Number Version: Status Author: Alison Cropper CL-CP/2009/010 V3 Final Job Title: Hospital Based Programme

More information

Scottish Cervical Screening Programme. Colposcopy and Programme Management

Scottish Cervical Screening Programme. Colposcopy and Programme Management Scottish Cervical Screening Programme Colposcopy and Programme Management Addendum to NHSCSP Publication No 20 Second Edition Exceptions Applicable in NHS Scotland April 2013 (Final Version 2.8 to incorporate

More information

The routine use of ZedScan within one colposcopy service in England. MC Macdonald, R Lyon, JE Palmer, JA Tidy

The routine use of ZedScan within one colposcopy service in England. MC Macdonald, R Lyon, JE Palmer, JA Tidy The routine use of ZedScan within one colposcopy service in England MC Macdonald, R Lyon, JE Palmer, JA Tidy Introduction Colposcopic impression alone has been shown to be subjective with variable rates

More information

ZedScan delivers improvements in clinical performance and more efficient patient management at Sheffield Teaching Hospitals NHS Foundation Trust

ZedScan delivers improvements in clinical performance and more efficient patient management at Sheffield Teaching Hospitals NHS Foundation Trust ZedScan Case Study NHS Hospital, UK. ZedScan delivers improvements in clinical performance and more efficient patient management at Sheffield Teaching Hospitals NHS Foundation Trust Increased detection

More information

An audit of liquid-based cervical cytology screening samples (ThinPrep and SurePath) reported as glandular neoplasia

An audit of liquid-based cervical cytology screening samples (ThinPrep and SurePath) reported as glandular neoplasia DOI:10.1111/j.1365-2303.2009.00695.x An audit of liquid-based cervical cytology screening samples (ThinPrep and SurePath) reported as glandular neoplasia S. A. Thiryayi, J. Marshall and D. N. Rana Manchester

More information

Northern Ireland Cervical Screening Programme

Northern Ireland Cervical Screening Programme Northern Ireland Cervical Screening Programme ANNUAL REPORT & STATISTICAL BULLETIN 2010-2011 1 Report produced by : Quality Assurance Reference Centre, PHA Date of Publication: September 2012 2 Contents

More information

CERVICAL SCREENING WALES CERVICAL SCREENING PROGRAMME, WALES: 2001/02

CERVICAL SCREENING WALES CERVICAL SCREENING PROGRAMME, WALES: 2001/02 CERVICAL SCREENING WALES INFORMATION TEAM STATISTICAL REPORT CERVICAL SCREENING PROGRAMME, WALES: 2001/02 For more information about this report contact: Helen Beer, Information Analyst / Manager, Screening

More information

ZedScan delivers improvements in clinical performance and more efficient patient management at Sheffield Teaching Hospitals NHS Foundation Trust

ZedScan delivers improvements in clinical performance and more efficient patient management at Sheffield Teaching Hospitals NHS Foundation Trust ZedScan Case Study NHS Hospital, UK. ZedScan delivers improvements in clinical performance and more efficient patient management at Sheffield Teaching Hospitals NHS Foundation Trust Increased detection

More information

National Cancer Peer Review Sarcoma. Julia Hill Acting Deputy National Co-ordinator

National Cancer Peer Review Sarcoma. Julia Hill Acting Deputy National Co-ordinator National Cancer Peer Review Sarcoma Julia Hill Acting Deputy National Co-ordinator Improving Outcomes Guidance The Intentions of Improving Outcomes for People with Sarcoma Changes in the provision of care

More information

KC53/61/65 Statistical Report Adroddiad Ystadegol 2012/13 Prepared by Cervical Screening Wales

KC53/61/65 Statistical Report Adroddiad Ystadegol 2012/13 Prepared by Cervical Screening Wales KC53/61/65 Statistical Report Adroddiad Ystadegol 2012/13 Prepared by Cervical Screening Wales CERVICAL SCREENING WALES STATISTICAL REPORT CERVICAL SCREENING PROGRAMME, WALES: 2012/2013 For more information

More information

Shared Care Pathway for Soft Tissue Sarcomas Presenting to Site Specialised MDTs. Gynaecological sarcomas Version 1

Shared Care Pathway for Soft Tissue Sarcomas Presenting to Site Specialised MDTs. Gynaecological sarcomas Version 1 Shared Care Pathway for Soft Tissue Sarcomas Presenting to Site Specialised MDTs Gynaecological sarcomas Version 1 Background This guidance is to provide direction for the management of patients with sarcomas

More information

GUIDELINES FOR CERVICAL CYTOLOGY SPECIMENS CA1066 (V8) Approved by Guidelines Assessment Panel

GUIDELINES FOR CERVICAL CYTOLOGY SPECIMENS CA1066 (V8) Approved by Guidelines Assessment Panel NORFOLK & WAVENEY CELLULAR PATHOLOGY SERVICE GUIDELINES FOR CERVICAL CYTOLOGY SPECIMENS CA1066 (V8) DEPT. SOP NO.:C.SC.I.806b EDITION: 8 AUTHORISED BY: See table below AUTHOR: VIKI FREW DATE OF ISSUE:

More information

WORKING TOGETHER FOR THE NHS 20/07/2018

WORKING TOGETHER FOR THE NHS 20/07/2018 20/07/2018 NHS Improvement and NHS England Wellington House 133-155 Waterloo Road London SE1 8UG 020 3747 0000 www.england.nhs.uk www.improvement.nhs.uk To: Regional Directors, Trust Medical Directors,

More information

Efficacy of cervical intrarepithelial neoplasia (CIN)

Efficacy of cervical intrarepithelial neoplasia (CIN) The Ulster Medical Journal, Volume 72, No. 1, pp. 10-15, May 2003. Efficacy of cervical intrarepithelial neoplasia (CIN) treatment by cold coagulation A Zawislak, J H Price, H R McClelland, R G N Storey,

More information

Northern Ireland cervical screening programme. Information for primary care and smear takers

Northern Ireland cervical screening programme. Information for primary care and smear takers Northern Ireland cervical screening programme Information for primary care and smear takers From January 2011, the Northern Ireland cervical screening programme will no longer invite women aged under 25

More information

Structured Training and Assessment: United Kingdom Perspective. Prof Maggie Cruickshank Past President of BSCCP University of Aberdeen Aberdeen UK

Structured Training and Assessment: United Kingdom Perspective. Prof Maggie Cruickshank Past President of BSCCP University of Aberdeen Aberdeen UK Structured Training and Assessment: United Kingdom Perspective Prof Maggie Cruickshank Past President of BSCCP University of Aberdeen Aberdeen UK Disclosures No financial relationships or conflict of interest

More information

UK National Screening Committee HPV as primary screen for cervical cancer - an evidence review. Consultation comments pro-forma.

UK National Screening Committee HPV as primary screen for cervical cancer - an evidence review. Consultation comments pro-forma. UK National Screening Committee HPV as primary screen for cervical cancer - an evidence review Consultation comments pro-forma Name: Sarah May Email address: sarahmay@ibms.org Organisation (if appropriate):

More information

SELF ASSESSMENT REPORT (MULTI-DISCIPLINARY TEAM)

SELF ASSESSMENT REPORT (MULTI-DISCIPLINARY TEAM) SELF ASSESSMENT REPORT (MULTI-DISCIPLINARY TEAM) Network Trust MDT MDT Lead Clinician ASWCN TAUNTON AND SOMERSET Taunton Lung MDT (11-2C-1) - 2011/12 Dr Sarah Foster Compliance Self Assessment LUNG MDT

More information

Keywords Cytology-screening, statistics-epidemiological surveys.

Keywords Cytology-screening, statistics-epidemiological surveys. DOI: 10.1111/j.1471-0528.2007.01467.x www.blackwellpublishing.com/bjog Epidemiology An examination of the role of opportunistic smear taking in the NHS cervical screening programme using data from the

More information

National Breast Cancer Audit next steps. Martin Lee

National Breast Cancer Audit next steps. Martin Lee National Breast Cancer Audit next steps Martin Lee National Cancer Audits Current Bowel Cancer Head & Neck Cancer Lung cancer Oesophagogastric cancer New Prostate Cancer - undergoing procurement Breast

More information

National Standards for Sarcoma Services

National Standards for Sarcoma Services National Standards for Sarcoma Services 2009 TABLE OF CONTENTS 1. INTRODUCTION TO THE NATIONAL CANCER STANDARDS...2 2. METHODOLOGY...4 3. FORMAT...4 4. INTRODUCTION TO SARCOMA...5 STANDARDS TOPIC: ORGANISATION...10

More information

How invasive cervical cancer audit affects clinical practice

How invasive cervical cancer audit affects clinical practice How invasive cervical cancer audit affects clinical practice Referring to NHSCSP and EU guidelines and audits in Southampton and London Amanda Herbert Guy s & St Thomas Foundation NHS Trust How invasive

More information

Activity Report April 2012 March 2013

Activity Report April 2012 March 2013 Gynaecological Cancer Managed Clinical Network Activity Report April 2012 March 2013 Nadeem Siddiqui MCN Clinical Lead Kevin Campbell Network Manager 1 CONTENTS EXECUTIVE SUMMARY 3 1. INTRODUCTION 4 2.

More information

National Standards for Sarcoma Services 2009

National Standards for Sarcoma Services 2009 National Standards for Sarcoma Services 2009 Crown copyright July 2010 F1101011 Contents 1. Introduction to the National Cancer Standards 2. Methodology 3. Format 4. Introduction to Sarcoma Standards Topic:

More information

Abnormal Smear (Cytology) Results What do they mean?

Abnormal Smear (Cytology) Results What do they mean? Abnormal Smear (Cytology) Results What do they mean? Obstetrics & Gynaecology Women & Children s Services This leaflet has been designed to give you important information about your condition / procedure,

More information

WIRRAL UNIVERSITY TEACHING HOSPITAL CYTOLOGY NHS CERVICAL SCREENING PROGRAMME INFORMATION PACK FOR SAMPLE TAKERS

WIRRAL UNIVERSITY TEACHING HOSPITAL CYTOLOGY NHS CERVICAL SCREENING PROGRAMME INFORMATION PACK FOR SAMPLE TAKERS Author J. Evans BMS 3 Authoriser A. Bamber Page 1 of 16 WIRRAL UNIVERSITY TEACHING HOSPITAL CYTOLOGY NHS CERVICAL SCREENING PROGRAMME INFORMATION PACK FOR SAMPLE TAKERS Author J. Evans BMS 3 Authoriser

More information

6 th EFC Satellite meeting, Saturday 1 st December 2018

6 th EFC Satellite meeting, Saturday 1 st December 2018 6 th EFC Satellite meeting, Saturday 1 st December 2018 Introduction Pekka Nieminen President-elect of the European Federation for Colposcopy, Department of Obstetrics and Gynaecology, Helsinki University

More information

Dear Colleagues, EXTENSION OF PAUSE TO THE USE OF VAGINAL MESH

Dear Colleagues, EXTENSION OF PAUSE TO THE USE OF VAGINAL MESH 29/03/2019 NHS Improvement and NHS England Wellington House 133-155 Waterloo Road London SE1 8UG 020 3747 0000 www.england.nhs.uk www.improvement.nhs.uk To: Regional Directors, Trust Medical Directors,

More information

Guideline for the Follow-up of Patients with Gynaecological Malignancies

Guideline for the Follow-up of Patients with Gynaecological Malignancies Guideline for the Follow-up of Patients with Gynaecological Malignancies Version History Version Date Summary of Change/Process 2.0 20.02.08 Endorsed by the Governance Committee 2.1 18.11.10 Circulated

More information

Guideline for the Management of Patients Suitable for Immediate Breast Reconstruction

Guideline for the Management of Patients Suitable for Immediate Breast Reconstruction Version History Guideline for the Management of Patients Suitable for Immediate Breast Reconstruction Version Summary of change Date Issued 2.0 Endorsed by the Governance Committee 20.02.08 2.1 Circulated

More information

Single Suspected Cancer Pathway Definitions pathway start date

Single Suspected Cancer Pathway Definitions pathway start date Single Suspected Cancer Pathway Definitions pathway start date Date: December 2018 Version: 8.0 Wales Cancer Owner: Network and Welsh Government Status Draft 1 P a g e Purpose of Document This document

More information

NHS Cervical Screening Programme in Kingston and Richmond ANNUAL REPORT

NHS Cervical Screening Programme in Kingston and Richmond ANNUAL REPORT Kingston Borough Team Richmond and Twickenham Borough Team 1. Introduction NHS Cervical Screening Programme in Kingston and Richmond ANNUAL REPORT 2010-12 All women between the ages of 25 and 64 are eligible

More information

The Role of The Advanced Practitioner in Cytology

The Role of The Advanced Practitioner in Cytology The Role of The Advanced Practitioner in Cytology Margaret Morgan Head of Service Cellular Pathology GSTS Pathology London Odense, Denmark 5 th March 2011 St Thomas Hospital London County Down Overview

More information

SMALL DESIGN SMART INNOVATION

SMALL DESIGN SMART INNOVATION SMALL DESIGN SMART INNOVATION The new Touch and Ultra Changing the Face of Colposcopy Significant improvements have changed the cervical cancer screening pathway over the last 20 years, resulting in high

More information

Integrated Cancer Services Action Plan. Colchester Hospital University NHS Foundation Trust 31 March 2014

Integrated Cancer Services Action Plan. Colchester Hospital University NHS Foundation Trust 31 March 2014 Integrated Cancer Services Action Plan Colchester Hospital University NHS Foundation Trust 31 March KEY Implemented, clearly evidenced and externally approved On Track to deliver Some issues narrative

More information

Clinical Guidance: Recommended Best Practices for Delivery of Colposcopy Services in Ontario Best Practice Pathway Summary

Clinical Guidance: Recommended Best Practices for Delivery of Colposcopy Services in Ontario Best Practice Pathway Summary Clinical Guidance: Recommended Best Practices for Delivery of Colposcopy Services in Ontario Best Practice Pathway Summary Glossary of Terms Colposcopy is the examination of the cervix, vagina and, in

More information

Effect of margin status on cervical intraepithelial neoplasia recurrence following LLETZ in women over 50 years

Effect of margin status on cervical intraepithelial neoplasia recurrence following LLETZ in women over 50 years DOI: 10.1111/j.1471-0528.2008.01853.x www.blackwellpublishing.com/bjog Gynaecological oncology Effect of margin status on cervical intraepithelial neoplasia recurrence following LLETZ in women over 50

More information

Cuid d Fheidhmeannacht na Seirbhíse Sláinte. Part of the Health Service Executive. CS/PR/PM-20 Rev 2 ISBN Programme Report 2014/2015

Cuid d Fheidhmeannacht na Seirbhíse Sláinte. Part of the Health Service Executive. CS/PR/PM-20 Rev 2 ISBN Programme Report 2014/2015 Programme Report 2014/2015 Contents Summary points 2 Introduction to the statistics 2014/2015 3 Part 1 Cervical screening activity 3 Programme coverage 4 Laboratory turnaround time 7 Notification of results

More information

Improving Outcomes for People with Sarcoma

Improving Outcomes for People with Sarcoma NHS National Institute for Health and Clinical Excellence Guidance on Cancer Services Improving Outcomes for People with Sarcoma List of All Recommendations March 2006 Developed for NICE by the National

More information

The implications of HPV immunisation on cervical screening

The implications of HPV immunisation on cervical screening The implications of HPV immunisation on cervical screening Dr Maggie Cruickshank Senior Lecturer in Gynaecology Scottish Cervical Cancer Prevention Programme (SCCPP) funded by CSO Cervical screening Detects

More information

Scottish Pathology Network (SPAN) Progress Report Oct 2008

Scottish Pathology Network (SPAN) Progress Report Oct 2008 Scottish Pathology Network (SPAN) Progress Report Oct 2008 SPAN SPAN Pathology configuration in Scotland Operation of the network Context (diagnostics in Scotland) Common challenges Concerted responses

More information

Audit Report Report of the 2010 Clinical Audit Data

Audit Report Report of the 2010 Clinical Audit Data Gynaecological Cancer Managed Clinical Network Audit Report Report of the Clinical Audit Data Nick Reed Consultant Clinical Oncologist MCN Clinical Lead (Joint) Nadeem Siddiqui Consultant Gynaecological

More information

INTERNAL VALIDATION REPORT (MULTI-DISCIPLINARY TEAM)

INTERNAL VALIDATION REPORT (MULTI-DISCIPLINARY TEAM) INTERNAL VALIDATION REPORT (MULTI-DISCIPLINARY TEAM) Network Trust MDT NECN N Tees & Hartlepool North Tees And Hartlepool Date Self Assessment Completed 23rd July 2009 Date of IV Review 19th June 2009

More information

Investigation of 100 consecutive negative cone biopsies

Investigation of 100 consecutive negative cone biopsies British Journal of Obstetrics and Gynaecology January 1997, Vol. 104, pp. 100-104 Investigation of 100 consecutive negative cone biopsies *Pouran Golbang Research Fellow and Consultant (Gynaecology), **James

More information

Ovarian cancer the need for change in service delivery in Northern Ireland

Ovarian cancer the need for change in service delivery in Northern Ireland The Ulster Medical Ovarian Journal, cancer Volume the need 72, for No. change 2, pp. in 93-97, service November delivery in 2003. Northern Ireland 93 Ovarian cancer the need for change in service delivery

More information

Shared Care Pathway for Soft Tissue Sarcomas Presenting to Site Specialised MDTs Lung /chest wall sarcomas incl. pulmonary metastatectomy Version 2

Shared Care Pathway for Soft Tissue Sarcomas Presenting to Site Specialised MDTs Lung /chest wall sarcomas incl. pulmonary metastatectomy Version 2 Shared Care Pathway for Soft Tissue Sarcomas Presenting to Site Specialised MDTs Lung /chest wall sarcomas incl. pulmonary metastatectomy Version 2 Background Sarcomas that arise in the lung de novo are

More information

Plus ça change. CWE Redman Colposcopy Symposium, ECC 2016

Plus ça change. CWE Redman Colposcopy Symposium, ECC 2016 Plus ça change. CWE Redman Colposcopy Symposium, ECC 2016 UHNM What we know HPV primary screening coming More sensitive: more HSIL detected Increase in workload Longer consultations More anxiety HPV Primary

More information

PEER REVIEW VISIT REPORT (MULTI-DISCIPLINARY TEAM)

PEER REVIEW VISIT REPORT (MULTI-DISCIPLINARY TEAM) PEER REVIEW VISIT REPORT (MULTI-DISCIPLINARY TEAM) Network Organisation (Trust) Team DCN POOLE Poole THYROID ONLY MDT (11-2I-2) - 2011/12 Peer Review Visit Date 18th August 2011 Compliance THYROID ONLY

More information

SELF ASSESSMENT REPORT (MULTI-DISCIPLINARY TEAM)

SELF ASSESSMENT REPORT (MULTI-DISCIPLINARY TEAM) SELF ASSESSMENT REPORT (MULTI-DISCIPLINARY TEAM) Network Trust MDT MDT Lead Clinician GMCN ROYAL WOLVERHAMPTON HOSPITALS The Royal Wolverhampton Hospitals Trust Lung MDT (11-2C-1) - 2011/12 Dr Angela Morgan

More information

A clinical review of borderline glandular cells reported on liquid-based cervical cytology

A clinical review of borderline glandular cells reported on liquid-based cervical cytology DOI: 10.1111/j.1471-0528.2009.02477.x www.bjog.org Gynaecological oncology A clinical review of borderline glandular cells reported on liquid-based cervical cytology A Patel, a N Thampy, b D Hemming, b

More information

SCREENING FOR BOWEL CANCER USING FLEXIBLE SIGMOIDOSCOPY REVIEW APPRAISAL CRITERIA FOR THE UK NATIONAL SCREENING COMMITTEE

SCREENING FOR BOWEL CANCER USING FLEXIBLE SIGMOIDOSCOPY REVIEW APPRAISAL CRITERIA FOR THE UK NATIONAL SCREENING COMMITTEE SCREENING FOR BOWEL CANCER USING FLEXIBLE SIGMOIDOSCOPY REVIEW APPRAISAL CRITERIA FOR THE UK NATIONAL SCREENING COMMITTEE The Condition 1. The condition should be an important health problem Colorectal

More information

The role of human papillomavirus testing in the management of women with low-grade abnormalities: multicentre randomised controlled trial

The role of human papillomavirus testing in the management of women with low-grade abnormalities: multicentre randomised controlled trial DOI: 10.1111/j.1471-0528.2010.02519.x www.bjog.org Epidemiology The role of human papillomavirus testing in the management of women with low-grade abnormalities: multicentre randomised controlled trial

More information

TESTING TIMES TO COME? AN EVALUATION OF PATHOLOGY CAPACITY IN NORTHERN IRELAND NOVEMBER 2016

TESTING TIMES TO COME? AN EVALUATION OF PATHOLOGY CAPACITY IN NORTHERN IRELAND NOVEMBER 2016 TESTING TIMES TO COME? AN EVALUATION OF PATHOLOGY CAPACITY IN NORTHERN IRELAND NOVEMBER 2016 EXECUTIVE SUMMARY Whilst cancer survival is at its highest ever level, our health services are under considerable

More information

4. Monitoring of PAP test with Cervical Biopsy Correlations

4. Monitoring of PAP test with Cervical Biopsy Correlations Page 1 of 6 1. For cases of an HSIL Pap test with a discordant biopsy report where only the biopsy report is available, what action do you take? (check all that apply) Paper correlation without review

More information

Activity Report March 2012 February 2013

Activity Report March 2012 February 2013 Lung Cancer Managed Clinical Network Activity Report March 2012 February 2013 John McPhelim Lead Lung Cancer Nurse MCN Clinical Lead Kevin Campbell Network Manager CONTENTS EXECUTIVE SUMMARY 3 1. INTRODUCTION

More information

Activity Report April 2012 to March 2013

Activity Report April 2012 to March 2013 North, South East and West of Scotland Cancer Networks Brain/Central Nervous System Tumours National Managed Clinical Network Activity Report April 2012 to March 2013 Professor Roy Rampling Emeritus Professor

More information

GYNECOLOGICAL PATHOLOGY FELLOWSHIP PROGRAM

GYNECOLOGICAL PATHOLOGY FELLOWSHIP PROGRAM GYNECOLOGICAL PATHOLOGY FELLOWSHIP PROGRAM The Department of Pathology and Laboratory Medicine University of Calgary, Faculty of Medicine Calgary Health Region and Calgary Laboratory Services Calgary,

More information

Surgeon workload and survival from breast cancer

Surgeon workload and survival from breast cancer British Journal of Cancer (2003) 89, 487 491 All rights reserved 0007 0920/03 $25.00 www.bjcancer.com Surgeon workload and survival from breast cancer J Stefoski Mikeljevic*,1, RA Haward 2,4, C Johnston

More information

Activity Report April 2013 March 2014

Activity Report April 2013 March 2014 North, South East and West of Scotland Cancer Networks Sarcoma National Managed Clinical Network Activity Report April 2013 March 2014 Dr Jeff White Consultant Oncologist NMCN Clinical Lead Lindsay Campbell

More information

cle Modern management of abnormal cervical smear Tint Tint Wai and Dilip Patil BJMP 2008:1(2) 18-22

cle Modern management of abnormal cervical smear Tint Tint Wai and Dilip Patil BJMP 2008:1(2) 18-22 BJMP 2008:1(2) 18-22 Review Articl cle Modern management of abnormal cervical smear Tint Tint Wai and Dilip Patil Abbreviations BSCCP British Society of Colposcopy and Cervical Pathology CIN Cervical intraepithelial

More information

Activity Report March 2013 February 2014

Activity Report March 2013 February 2014 West of Scotland Cancer Network Skin Cancer Managed Clinical Network Activity Report March 2013 February 2014 Dr Girish Gupta Consultant Dermatologist MCN Clinical Lead Tom Kane MCN Manager West of Scotland

More information

DIRECTED WORKPLACE-BASED ASSESSMENTS BY STAGES OF TRAINING AND OPTIONAL PACKAGES

DIRECTED WORKPLACE-BASED ASSESSMENTS BY STAGES OF TRAINING AND OPTIONAL PACKAGES DIRECTED WORKPLACE-BASED ASSESSMENTS BY STAGES OF TRAINING AND OPTIONAL PACKAGES The following are lists of workplace-based assessments, from which should be selected appropriate examples to make up the

More information

Treatment of Cervical Intraepithelial Neoplasia. Case. How would you manage this woman?

Treatment of Cervical Intraepithelial Neoplasia. Case. How would you manage this woman? Treatment of Cervical Intraepithelial Neoplasia Karen Smith-McCune Professor, Department of Obstetrics, Gynecology and Reproductive Sciences I have no conflicts of interest Case How would you manage this

More information

LCA Lung Clinical Forum. 21 st October 2014

LCA Lung Clinical Forum. 21 st October 2014 LCA Lung Clinical Forum 21 st October 2014 Welcome Dr Liz Sawicka Chair - LCA Lung Pathway Group Succession planning Dr Kate Haire Consultant in Public Health Medicine, LCA Commissioning Intentions for

More information

Activity Report April 2012 March 2013

Activity Report April 2012 March 2013 Colorectal Cancer Managed Clinical Network Activity Report April 2012 March 2013 Paul Horgan Professor of Surgery MCN Clinical Lead Kevin Campbell Network Manager 1 CONTENTS EXECUTIVE SUMMARY 3 1. INTRODUCTION

More information

!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$

!#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$ !"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$ Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology

More information

Cervical Cancer Screening. David Quinlan December 2013

Cervical Cancer Screening. David Quinlan December 2013 Cervical Cancer Screening David Quinlan December 2013 Cervix Cervical Cancer Screening Modest variation provincially WHO and UK begin at 25 stop at 60 Finland begin at 30 stop at 60 Rationale for

More information

MasDA Mastectomy Decisions Audit 2015

MasDA Mastectomy Decisions Audit 2015 MasDA Mastectomy Decisions Audit 2015 AUDIT PROTOCOL FULL TITLE Mastectomy Decisions Audit: a prospective, multi-centre, population-based audit SHORT TITLE MasDA CHIEF INVESTIGATORS Mrs Jagdeep K Singh,

More information

Trust Guideline for the inclusion of women at High Risk of Breast Cancer in the NHS Breast Screening Programme

Trust Guideline for the inclusion of women at High Risk of Breast Cancer in the NHS Breast Screening Programme Trust Guideline for the inclusion of women at High Risk of Breast Cancer in the NHS Breast Screening Programme For Use in: By: For: Division responsible for document: Key words: Name and job title of document

More information

NHSCSP proposals for cervical screening intervals. Comments and recommendations of Council of the British Society for Clinical Cytology

NHSCSP proposals for cervical screening intervals. Comments and recommendations of Council of the British Society for Clinical Cytology NHSCSP proposals for cervical screening intervals Comments and recommendations of Council of the British Society for Clinical Cytology The following paper is written on behalf of BSCC Council to express

More information

Understanding lymphoma: the importance of patient data

Understanding lymphoma: the importance of patient data Understanding lymphoma: the importance of patient data Introduction what is a cancer registry and why is it important? Cancer registries collect detailed, personalised information and data about cancer

More information

Defining quality in ovarian cancer services: the patient perspective

Defining quality in ovarian cancer services: the patient perspective Defining quality in ovarian cancer services: the patient perspective 1 Contents Introduction... 3 Awareness and early diagnosis... 4 Information and support... 5 Treatment and care... 6 Living with and

More information

COLPOSCOPY QUALITY IMPROVEMENT PROGRAM (C QuIP) VICTORIAN CERVICAL CYTOLOGY REGISTRY PILOT STUDY. Dorota Gertig, Marion Saville

COLPOSCOPY QUALITY IMPROVEMENT PROGRAM (C QuIP) VICTORIAN CERVICAL CYTOLOGY REGISTRY PILOT STUDY. Dorota Gertig, Marion Saville COLPOSCOPY QUALITY IMPROVEMENT PROGRAM (C QuIP) VICTORIAN CERVICAL CYTOLOGY REGISTRY PILOT STUDY Dorota Gertig, Marion Saville on behalf of the C QuIP Steering Committee June 2013 1 CONTENTS 1. Executive

More information

Management that provides continuity of care for women

Management that provides continuity of care for women Management that provides continuity of care for women If women are diagnosed with reproductive tract infection, prompt treatment should be instituted according to the WHO guidelines. Though it may be preferred

More information

Work Programme/Service Delivery Plan 2010/2013

Work Programme/Service Delivery Plan 2010/2013 Essex and East Suffolk Gynaecological Cancer Network Site Specific Group Work Programme/Service Delivery Plan 2010/2013 Version Number 1.2 Author Members of the NSSG Date Written June 2010 Reviewed May

More information

Commissioning Chemotherapy Services Conference. Issues of consent in systemic therapy

Commissioning Chemotherapy Services Conference. Issues of consent in systemic therapy Commissioning Chemotherapy Services Conference Issues of consent in systemic therapy Dr Janine Mansi Consultant Medical Oncologist 28 th November 2017 Introduction Background and context What we have done

More information

Urgent referral for suspected cancer in Scotland

Urgent referral for suspected cancer in Scotland 270 Oncology Urgent referral for suspected cancer in Scotland Cancer is a common problem, but an individual GP may only see about seven to eight new cases of cancer per annum (although they will see many

More information

Ovarian Cancer Quality Performance Indicators

Ovarian Cancer Quality Performance Indicators Ovarian Cancer Quality Performance Indicators Patients diagnosed between October 2013 and September 2016 Publication date 20 February 2018 An Official Statistics publication for Scotland This is an Official

More information

2. CANCER AND CANCER SCREENING

2. CANCER AND CANCER SCREENING 2. CANCER AND CANCER SCREENING INTRODUCTION The incidence of cancer and premature mortality from cancer are higher in Islington compared to the rest of England. Although death rates are reducing, this

More information

Activity Report July 2014 June 2015

Activity Report July 2014 June 2015 West of Scotland Cancer Network Gynaecological Cancer Managed Clinical Network Activity Report July 2014 June 2015 Nadeem Siddiqui Consultant Gynaecological Oncologist MCN Clinical Lead Kevin Campbell

More information

STANDARDS FOR UPPER GI CANCERS 2004

STANDARDS FOR UPPER GI CANCERS 2004 STANDARDS FOR UPPER GI CANCERS 2004 Source: CSCG Title: UPPER GI CANCERS STANDARDS Version: 10/CONSULTATION Page 1 of 33 1. INTRODUCTION TO THE CANCER STANDARDS 1.1 These Cancer Standards replace the previous

More information

THE NEW ZEALAND MEDICAL JOURNAL

THE NEW ZEALAND MEDICAL JOURNAL THE NEW ZEALAND MEDICAL JOURNAL Vol 8 No ISSN 75 876 Findings and outcome of teenage women referred for colposcopy at Christchurch Women s Hospital, New Zealand Peter Sykes, Dianne Harker, David Peddie

More information

Activity Report April 2013 March 2014

Activity Report April 2013 March 2014 North, South East and West of Scotland Cancer Networks HepatoPancreatoBiliary Cancers National Managed Clinical Network Activity Report April 2013 March 2014 Mr Colin McKay Consultant Surgeon NMCN Clinical

More information

The Hepatitis C Action Plan for Scotland: Draft Guidelines for Hepatitis C Care Networks

The Hepatitis C Action Plan for Scotland: Draft Guidelines for Hepatitis C Care Networks The Hepatitis C Action Plan for Scotland: Draft Guidelines for Hepatitis C Care Networks Royal College of Physicians of Edinburgh Friday 12 October 2007 CONTENTS 1.0 ACCOUNTABILITY AND ORGANISATION 2.0

More information

QA Processes. Philip DaCosta BSCP QA Lead, Yorkshire & the Humber September 2013

QA Processes. Philip DaCosta BSCP QA Lead, Yorkshire & the Humber September 2013 QA Processes Philip DaCosta BSCP QA Lead, Yorkshire & the Humber September 2013 Standards QA visits Dashboards BCSP standards Standards for Organisation Service delivery Reporting Data quality Audit and

More information

NATIONAL CERVICAL CANCER SCREENING PROGRAMME Monitor 2017

NATIONAL CERVICAL CANCER SCREENING PROGRAMME Monitor 2017 a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a NATIONAL CERVICAL CANCER SCREENING PROGRAMME Monitor

More information

Re-audit of Radiotherapy Waiting Times in the United Kingdom, 2007

Re-audit of Radiotherapy Waiting Times in the United Kingdom, 2007 Re-audit of Radiotherapy Waiting Times in the United Kingdom, 2007 K. J. Drinkwater, M. V. Williams The Royal College of Radiologists, 38 Portland Place, London W1B 1JQ, UK ABSTRACT: This is the fourth

More information

Single Suspected Cancer Pathway Definitions pathway start date

Single Suspected Cancer Pathway Definitions pathway start date Single Suspected Cancer Pathway Definitions pathway start date Date: March 2018 Version: 1.2.1 Wales Cancer Owner: Network and Welsh Government Status Published 1 P a g e Purpose of Document This document

More information

The society for lower genital tract disorders since 1964.

The society for lower genital tract disorders since 1964. The society for lower genital tract disorders since 1964. Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology

More information

Re-audit of Radiotherapy Waiting Times 2005

Re-audit of Radiotherapy Waiting Times 2005 Abstract Re-audit of Radiotherapy Waiting Times 2005 E. Summers, M Williams Royal College of Radiologists, 38 Portland Place, London W1B 4JQ, UK Aim: To determine current waiting times for radiotherapy

More information

Screen-detected invasive cervical carcinoma and its clinical significance during the introduction of organized screening

Screen-detected invasive cervical carcinoma and its clinical significance during the introduction of organized screening DOI: 10.1111/j.1471-0528.2008.01989.x www.blackwellpublishing.com/bjog Epidemiology Screen-detected invasive cervical carcinoma and its clinical significance during the introduction of organized screening

More information

National Prostate Cancer Audit. Bill Cross June 2015

National Prostate Cancer Audit. Bill Cross June 2015 National Prostate Cancer Audit Bill Cross June 2015 National Prostate Cancer Audit aim of assessing the process of care and its outcomes in men diagnosed with prostate cancer in England and Wales National

More information

Activity Report July 2012 June 2013

Activity Report July 2012 June 2013 Urological Cancers Managed Clinical Network Activity Report July 2012 June 2013 Mr Seamus Teahan Consultant Urologist MCN Clinical Lead Tom Kane MCN Manager 1 CONTENTS EXECUTIVE SUMMARY 3 1. INTRODUCTION

More information

The Constitution of the British Association for Chronic Fatigue Syndrome/ME (BACME) CONTENTS. Name of the Organisation. 2. Aims and Objectives

The Constitution of the British Association for Chronic Fatigue Syndrome/ME (BACME) CONTENTS. Name of the Organisation. 2. Aims and Objectives The Constitution of the British Association for Chronic Fatigue Syndrome/ME (BACME) October 2013 CONTENTS Name of the Organisation 1. History 2. Aims and Objectives 3. Membership of BACME 4. BACME executive

More information

NHSCSP AUDIT OF INVASIVE CERVICAL CANCER: NATIONAL REPORT

NHSCSP AUDIT OF INVASIVE CERVICAL CANCER: NATIONAL REPORT NHSCSP AUDIT OF INVASIVE CERVICAL CANCER: NATIONAL REPORT 2009-2012 NHSCSP audit of invasive cervical cancer: national report 2009-2012 i Lead Authors Professor Peter Sasieni Professor of Biostatistics

More information

National Cancer Programme. Work Plan 2015/16

National Cancer Programme. Work Plan 2015/16 National Cancer Programme Work Plan 2015/16 Citation: Ministry of Health. 2015. National Cancer Programme: Work plan 2015/16. Wellington: Ministry of Health. Published in October 2015 by the Ministry of

More information

Fixing footcare in Sheffield: Improving the pathway

Fixing footcare in Sheffield: Improving the pathway FOOTCARE CASE STUDY 1: FEBRUARY 2015 Fixing footcare in Sheffield: Improving the pathway SUMMARY The Sheffield Teaching Hospitals NHS Foundation Trust diabetes team transformed local footcare services

More information

Downloaded from:

Downloaded from: Morris, M. ; Quaresma, M. ; Pitkniemi, J. ; Morris, E. ; Rachet, B. ; Coleman, M.P. (2016) [Accepted Manuscript] Do cancer survival statistics for every hospital make sense? The lancet oncology. ISSN 1470-2045

More information

Cervical cancer screening in Norway

Cervical cancer screening in Norway Cervical cancer screening in Norway «The future of cancer screening in Estonia: health benefits and best practices» 17 November 2016, Tartu Stefan Lönnberg Cancer Registry of Norway Screening governance

More information

Cervical Screening. Bexley Bromley and Greenwich (BBG) Annual Report 2009/10. Dr Angela Bhan Screening Commissioner

Cervical Screening. Bexley Bromley and Greenwich (BBG) Annual Report 2009/10. Dr Angela Bhan Screening Commissioner Cervical Screening Bexley Bromley and Greenwich (BBG) Annual Report 2009/10 Dr Angela Bhan Screening Commissioner 1 Contents EXECUTIVE SUMMARY 3 1. NHS Cervical Screening Programme 1.1 Local programme

More information